The lack of universal access to sex education in the country has led many young people to face unwanted pregnancies due to a lack of proper knowledge of contraception, while “human flow” and “drug flow” are the main ways to terminate pregnancy during early pregnancy, and most people are unaware of the differences in conditions and risks that apply. The following is a synthesis of key messages from the “time horizons, core differences, risk comparisons” to help scientific judgement choices。
I. Premises: definition of 2 keys - purpose of precentage and imagine
Either way, two core premises need to be met before serious risks may arise:
Identification of pregnancy, stage of treatment
The method of termination of pregnancy must be strictly chosen in accordance with the pregnancy week and the programme must be adjusted beyond the corresponding time frame:
Pregnancy 14-28 weeks: “livannor ambulatory inoculation”, after the birth of the foetus has been terminated by drug use, after which the vaginal delivery (like the production process) is excreted, and lastly cleared of the palace, which is not part of the normal human flow/drug flow
(a) over 28 weeks: non-medical induced labour is prohibited by law, except for medical indications (e. G. Foetal malformation, serious maternal illness)
Within 12 weeks of pregnancy (early pregnancy): a choice may be made between a human flow or a drug flow, in which the drug flow is more time-bound (within 49 days of pregnancy) and a human flow can cover up to 12 weeks of pregnancy (the procedure needs to be adjusted to the size of the embryo)。
"intra-uterine pregnancy" must be recognized, and extra-uterine pregnancy must be eliminated
The flow of people and medicine only applies to the normal pregnancy of “fertilized eggs in the womb”. In the case of extrauterine pregnancy (preferably fertilized eggs laid in an extrauterine position such as a ovary tube), the blind choice of human flow / drug flow is not only ineffective, but may also delay the treatment of extrauterine pregnancy, which may lead to a breakdown of the tubal, haemorrhaging or even endangering life。
The termination programme is usually established after 5 weeks of pregnancy (suspension of more than 35 days) by means of the ultra-observed uterus b, combined with blood hcg tests。
Core differences: conditions applicable to human and drug flows, process differences
There are significant differences between the two in terms of “time limits, mode of operation, periodicity”, which directly affect the direction chosen:
Relative dimensions
Medical abortion (drug flow)
Abortion (human flow)
Time of application
Strictly limited to 49 days of pregnancy (some of the literature suggests pregnancy for more than 36 days to avoid the drug sensitivity of the embryo being too small)
10-12 weeks of pregnancy
- ten weeks: scratch
- pregnancy 10-12 weeks: scratch (first, big tissue, then palace)
Operation
Oral drug termination of pregnancy: the conventional program is "mifestone + misoupol", administered in 3 days, 3 days after taking the drug and extracting embryos through uterus contraction
Surgical operations: equipping embryos through apparatus into the ceremonial cavity, two types of anesthesia -
- regular flow: local anaesthesia (injection of anaesthesia at the edge of the palace, awakening in surgery)
- no pain in the flow of human beings: iva (unintended in art, under the supervision of a professional anesthesiologist)
Completion cycle
Longer, approximately 3 days (medicine + tyre) with 1 - 2 hours of post-temporal observation and subsequent review to confirm cleanness
Shorter, single operation 5-10 minutes, post-operative observation 1-2 hours to leave the hospital, 1 week or so
Key features
No cavity, dependence on drugs for natural fetuses
It's ceremonial. It's a direct removal of embryo tissue
Iii. Risks versus effects: impairments, success rates, differences in complications
The choice needs to focus on the “success rate” and the “future damage”, which have advantages and disadvantages and are weighed against their own circumstances:
Success rate: higher human flow and secondary treatment for drug failure
(a) drug flow: the success rate is about 90 per cent and the reasons for failure are mostly “incomplete discharge of the embryo” (cervix residue), in the form of prolonged bleeding (more than 2 weeks) after taking the drug, constant haemorrhage, followed by “cleaning” (similar to small human flow) equivalent to secondary damage by means of b super-identifying residuals
Human flow: the success rate is close to 95 per cent (excludes special circumstances such as abnormal embryo position), because the embryo can be removed directly through the device in the operation, with a lower probability of leakage, residuals, and most can be completed at once without secondary operation。
2. Level of impairment: drug flow has a lower level of cervix damage and higher risk of human flow surgery
(a) drug flow advantages: the absence of uterine devices, the low direct damage to the uterine membrane, the lower probability of long-term complications such as “uterine viscosity” after the operation, and the relatively lower impact on subsequent fertility
Shortcomings of the drug flow: long bleeding (average of 7-14 days) and extended vaginal haemorrhage may increase the risk of infection with “basic cavity” “intrauterine inflammation”, requiring attention to post-operative hygiene, avoiding tubal bathing and sexual life。
Human flow risk: risks associated with surgery: uterine cavity may lead to uterine membrane damage (excessive laceration), uterine perforation (frequent but severe, requiring surgical repair), uterine viscosity (which may lead to closure, infertility), additional risk of painless human flow: risk of anaesthesia, respiratory inhibition, etc., and unconscious inability to cooperate with a doctor during surgery may delay detection of abnormal conditions such as “uterine perforation”; post-operative infections: infections such as pelvic inflammation may also occur if surgical sterilization is not strict or post-operative care is inadequate。
Special error zone clarification: “a painless flow = no harm” “a visual flow = absolute safety”
(a) the pain-free flow only addresses the problem of “artificial pain”, does not reduce the damage to the cervix caused by the operation, but increases the additional risk of anaesthesia and is not a “safer” option
Visibility of human flow through b super-surveillance operations reduces the probability of residual, perforated, but is not “directly visible to the naked eye”, remains dependent on medical experience and does not fully avoid risk, and most regular hospitals now have b super-surveillance as a routine human flow configuration, not a special “high-end technology”。
Iv. Summary: how? Core principles and pit avoidance recommendations
1. Prioritization of time: within 49 days of pregnancy, preference is given to the flow of medicine if it wishes to reduce cervix damage, accept a longer haemorrhage cycle and 90% success rate; pregnancy between 49 and 12 weeks, or if the flow fails。
2. In combination with their own circumstances: if there is a strong fear of surgery, a history of drug-free allergies (e. G., mifisketone) and a guarantee of post-operative rest and hygiene, a drug flow may be selected; if there is a desire to complete it quickly, to avoid long-term haemorrhages and secondary clearance risks, or a drug flow taboo (e. G. Abnormal liver and kidney function, glaucoma eyes), a human flow may be selected (common or pain-free flow needs to be weighed against the risk of anaesthesia)。
Key pits: rejection of “abortion as an alternative to contraception”. Drug and human flows are “remedial measures for unwanted pregnancies” rather than conventional methods of contraception. Even the smaller drug flows are at a much higher risk than scientific methods such as the “condom” “short-act oral contraceptives”. Proper contraception (e. G. Full-time condom use and regular use of short-acting contraceptives) is fundamental to avoiding unwanted pregnancies and abortion injuries。
